Bone targeted treatments have transformed the quality of life and physical functioning of patients with metastatic bone disease and, in certain circumstances, have been shown to prevent the development of bone metastases and improve survival. However, the steps in development of these agents have been somewhat disjointed and based on good fortune as well as scientific endeavour and rational clinical development.
No takes yet. Share an insight, caveat, or question.
Robert E. Coleman (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: